$ILMN

Meister Keith A. sold $15.3M of ILMN (indirect holdings)

Meister Keith A. sold 92,877 indirectly-held shares of ILLUMINA, INC. (ILMN) at $164.56 ($15.28M total) on 2026-05-29.

Original reporting
SEC EDGAR · Meister Keith A.
Published Jun 1, 2026, 10:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ILMN
Neutral
medium confidence
Mentioned
$ILMN
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

Traders may monitor for additional insider activity or whether the sale coincides with any upcoming company-specific catalysts, but the disclosure alone is unlikely to reset valuation.

02

Market read

A notable-size insider sale is disclosed, which can influence short-term sentiment but lacks fundamental event content.

03

What to watch

The sale is not explicitly tied to a 10b5-1 plan (per article), which can draw trader attention, but the filing still provides no reason for the transaction or any change in company outlook.

Relevance 6/10Novelty 6/10Timing: After-hours/next-session positioning following today’s SEC Form 4 filing (filed 2026-06-01).

Background

SEC Form 4 reports insider transactions; this filing documents an open-market sale by an Illumina director.

Company-level read

Ticker impact

$ILMNNeutralMedium confidence
Context

Illumina director Keith A. Meister sold 92,877 shares in an open-market transaction worth about $15.28M, disclosed via SEC Form 4.

Expected impact

Low probability of sustained price impact; any reaction is likely short-lived unless follow-on selling or new fundamentals emerge.

Evidence & confidence

The filing is a disclosed sale (not a buy), but it is not tied to earnings, guidance, or a corporate event; also the plan is stated as not pre-arranged 10b5-1, which can increase attention but still lacks fundamental linkage.

Market effects

Minimal; this is company-specific insider activity without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

A single director sale may reflect diversification or liquidity needs rather than a bearish view, especially with no accompanying corporate news.

Key entities

  • Illumina, Inc.

    Subject of the SEC Form 4 insider sale by director Keith A. Meister.

  • Keith A. Meister

    Illumina director who sold 92,877 shares at $164.56/share for ~$15.28M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNMed

Does Illumina’s (ILMN) New Credit Line Quietly Redefine Its Risk Buffer and Strategic Flexibility?

Illumina (ILMN) secured a new $1.00 billion revolving credit facility, replacing its 2023 agreement. The facility offers variable-rate borrowing and covenant limits, with no amounts drawn initially. This enhances liquidity and financial flexibility amid stronger revenue and earnings guidance. The company's focus remains on clinical sequencing, with risks including competition, China exposure, and research funding. Analysts' revenue growth expectations vary, with some projecting 5.2% annual growt

$ILMNMedAI 8/10

Illumina Stock Is Up 82% in Six Months. The Street’s Target Still Trails It.

Illumina (ILMN) stock has risen 82% in six months, closing at $223.22 on August 24. The surge follows three quarters of raised guidance due to strong clinical sequencing demand. Analysts' average price target is $199, 11% below the current price. TIKR's model values the stock at $259 by late 2030, implying a 16% total return. Potential S&P 500 inclusion adds speculative momentum.

$ILMNHighAI 8/10

Illumina (ILMN) Replaces Prior Deal With $1 Billion Revolving Credit Facility

Illumina (ILMN) has secured a new $1 billion unsecured revolving credit facility, replacing its prior agreement. The facility offers updated covenants and increased flexibility for future financing. According to the company, it will serve as a liquidity backstop and support capital structure decisions. The credit line is expected to fund working capital, equipment, and potential projects, but may impact debt-to-equity metrics if not matched by earnings growth.

$MRNAMedAI 8/10

Three Cancer Research Stocks to Watch After Moderna’s Breakthrough

Moderna's [MRNA] personalized mRNA cancer vaccine, intismeran, met Phase 3 trial endpoints, boosting its shares and Merck's [MRK] as it's administered with Keytruda. Illumina [ILMN] and Pacific Biosciences [PACB] also rose due to their sequencing technology's role. BioNTech [BNTX] gained as investors reassessed mRNA cancer therapies. Moderna reported Q2 revenue of $145M and a net loss of $782M, while Illumina reported Q2 revenue of $1.16B and raised 2026 guidance. BioNTech reported Q2 revenue of